We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

79 hedge funds and large institutions have $843M invested in Phathom Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 14 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 14

1.14% more ownership

Funds ownership: 78.4% → 79.54% (+1.1%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

6% less funds holding

Funds holding: 84 → 79 (-5)

8% less capital invested

Capital invested by funds: $919M → $843M (-$75.8M)

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

Holders
79
Holders Change
-5
Holders Change %
-5.95%
% of All Funds
1.38%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
12
Increased
34
Reduced
14
Closed
17
Calls
$339K
Puts
–
Net Calls
+$339K
Net Calls Change
+$342K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.3M
2
RCAMU
Rothschild & Co Asset Management US
Connecticut
+$6.14M
3
State Street
State Street
Massachusetts
+$4.41M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$4.13M
5
WCM Investment Management
WCM Investment Management
California
+$3.72M

Top Sellers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
-$9.74M
2
CCM
CAAS Capital Management
New York
-$7.92M
3
JP Morgan Chase
JP Morgan Chase
New York
-$6.52M
4
Marshall Wace
Marshall Wace
United Kingdom
-$3.01M
5
WP
Woodline Partners
California
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
NFSG
76
Newbridge Financial Services Group
Florida
$1K – – –
US Bancorp
77
US Bancorp
Minnesota
$1K +$609 +17 New
AIG
78
American International Group
New York
$384 +$165K +4,601 +68%
CCM
79
CAAS Capital Management
New York
– -$7.92M -210,973 Closed
WP
80
Woodline Partners
California
– -$1.56M -41,678 Closed
PHP
81
Parkman Healthcare Partners
Connecticut
– -$1.14M -30,207 Closed
Aviva
82
Aviva
United Kingdom
– -$1.11M -29,463 Closed
California Public Employees Retirement System
83
California Public Employees Retirement System
California
– -$1.1M -29,400 Closed
Susquehanna International Group
84
Susquehanna International Group
Pennsylvania
– -$949K -26,505 Closed
Canada Pension Plan Investment Board
85
Canada Pension Plan Investment Board
Ontario, Canada
– -$751K -20,000 Closed
Millennium Management
86
Millennium Management
New York
– -$454K -12,090 Closed
Renaissance Technologies
87
Renaissance Technologies
New York
– -$424K -11,300 Closed
Squarepoint
88
Squarepoint
New York
– -$420K -11,186 Closed
Jane Street
89
Jane Street
New York
– -$308K -8,193 Closed
ECM
90
ExodusPoint Capital Management
New York
– -$283K -7,534 Closed
CPIG
91
Chicago Partners Investment Group
Illinois
– -$206K -5,266 Closed
Wells Fargo
92
Wells Fargo
California
– -$132K -3,527 Closed
HPC
93
HM Payson & Co
Maine
– -$14K -365 Closed
Bank of Montreal
94
Bank of Montreal
Ontario, Canada
– -$13K -341 Closed
VFA
95
Valeo Financial Advisors
Indiana
– -$6K -151 Closed
1 2 3
4

PHAT Hedge Fund Activity: Q2 2021 in Review

79 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2021, worth a combined $843M — down 8.2% from $919M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PHAT and 12 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 34 added.

The largest buyer was BlackRock, adding an estimated $12.3M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $9.74M.

  • 79 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2021, down from 84 in Q1 2021.
  • Funds reported $843M of Phathom Pharmaceuticals stock for Q2 2021, down 8.2% quarter-over-quarter.
  • 12 funds opened new Phathom Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of -5 holders.
  • The largest Phathom Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $12.3M added.
  • The largest Phathom Pharmaceuticals seller in Q2 2021 was Gilder Gagnon Howe & Co, an estimated $9.74M sold.

Based on aggregated 13F filings for Q2 2021.